DualityBio Inc.
Headquarters country
China
Registry sponsor category
Industry
- Other names
- DualityBio Inc.
- Company name
- DualityBio Inc.
- Organisation type
- Industry
- Registered legal name
- DualityBio Ltd.
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 254900Z8UPKB281ALA67
Related records
Trials (16)
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- A Study of DB-1202 Monotherapy in Advanced Solid Tumors
- A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
- A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
- A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
- First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors